Hikma Narrows Annual Profit Forecast
Hikma Pharmaceuticals narrowed its annual profit forecast range to between 740 million and 760 million dollars. Strong demand for branded medicines in the Middle East and North Africa drove the growth. The drugmaker also maintained its overall annual revenue growth target.
Xurve View
Insights:
Xurve View
Hikma Pharmaceuticals plc narrowed its full-year operating profit forecast to a range of $740 million to $760 million on Thursday morning, driven by strong demand in its branded division. The updated guidance tightens the lower end from a previous forecast of $720 million to $770 million. The United Kingdom drugmaker is leaning on robust Middle East and North Africa operations to offset headwinds in its injectables unit.
